テリパラチド投与期間がデノスマブ療法前の骨代謝および骨密度に及ぼす影響の検討

基本情報

NCT ID

NCT03702140

ステータス

不明

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

90

治験依頼者名

Shinshu University

概要

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: 1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. 2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months. 3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)